Wockhardt Limited

NSEI:WOCKPHARMA Stock Report

Market Cap: ₹190.9b

Wockhardt Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Wockhardt.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth17.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up

Nov 02
Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up

What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You

Aug 20
What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You

Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Jul 27
Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Jun 30
Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation

Jun 22
Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation

Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%

Feb 21
Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%

There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump

Dec 19
There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump

There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues

Oct 14
There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues

Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?

Jun 23
Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?

Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Feb 18
Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Jan 04
Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being

Jul 26
Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being

Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

May 18
Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Jan 26
Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)

What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?

Dec 01
What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wockhardt has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:WOCKPHARMA - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202429,810-2,880-1,7801,470N/A
6/30/202429,250-3,430N/AN/AN/A
3/31/202428,300-4,630302,190N/A
12/31/202327,760-5,010N/AN/AN/A
9/30/202327,740-5,140201,960N/A
6/30/202327,000-6,260N/AN/AN/A
3/31/202326,570-5,590-5601,530N/A
12/31/202226,280-6,100N/AN/AN/A
9/30/202227,820-5,2102402,250N/A
6/30/202229,650-2,980N/AN/AN/A
3/31/202232,300-2,4402,0104,130N/A
12/31/202132,074-787N/AN/AN/A
9/30/202131,175-5671,7142,857N/A
6/30/202129,696-867N/AN/AN/A
3/31/202127,080-2,990-3,570-2,870N/A
12/31/202027,633-1,780N/AN/AN/A
9/30/202024,910-2,583-2,486-896N/A
6/30/202027,167-3,181N/AN/AN/A
3/31/202028,440-1,6384,7666,490N/A
12/31/201935,136-1,320N/AN/AN/A
9/30/201936,903-2,1274,7857,311N/A
6/30/201940,138-1,533N/AN/AN/A
3/31/201935,658-2,897-9151,833N/A
12/31/201841,851-3,346N/AN/AN/A
9/30/201841,445-3,043N/AN/AN/A
6/30/201840,536-2,848N/AN/AN/A
3/31/201839,245-6,083N/A684N/A
12/31/201737,822-6,285N/AN/AN/A
9/30/201737,724-6,416N/AN/AN/A
6/30/201738,148-6,213N/AN/AN/A
3/31/201739,664-1,957N/A-2,695N/A
12/31/201641,695485N/AN/AN/A
9/30/201642,4851,745N/AN/AN/A
6/30/201644,1342,499N/AN/AN/A
3/31/201644,5322,507N/A716N/A
12/31/201546,0853,168N/AN/AN/A
9/30/201549,1486,031N/AN/AN/A
6/30/201545,4974,992N/AN/AN/A
3/31/201544,8154,049N/A3,550N/A
12/31/201443,8674,452N/AN/AN/A
9/30/201442,4104,024N/AN/AN/A
6/30/201444,6325,374N/AN/AN/A
3/31/201448,3048,407N/A14,763N/A
12/31/201352,77211,010N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if WOCKPHARMA's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if WOCKPHARMA's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if WOCKPHARMA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if WOCKPHARMA's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if WOCKPHARMA's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if WOCKPHARMA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y